These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17571579)

  • 21. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
    Stasi R; Evangelista ML; Stipa E; Buccisano F; Venditti A; Amadori S
    Thromb Haemost; 2008 Jan; 99(1):4-13. PubMed ID: 18217129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TPO-receptor agonists in ITP: a clinician's navigation between Scylla and Charybdis.
    Rodeghiero F
    Am J Hematol; 2012 Oct; 87(10):943. PubMed ID: 22847599
    [No Abstract]   [Full Text] [Related]  

  • 23. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
    Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
    Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
    [No Abstract]   [Full Text] [Related]  

  • 24. Simultaneous romiplostin, eltrombopag, and prednisone were successful in severe thrombocytopenia of Evans syndrome refractory to hydrocortisone, splenectomy, intravenous IgG, and rituximab.
    Ruiz-Arguelles GJ; Ruiz-Delgado GJ; Velázquez-Sánchez-de-Cima S; Zamora-Ortiz G
    Hematology; 2013 May; 18(3):175-7. PubMed ID: 23321502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on romiplostim and eltrombopag indirect comparison.
    Cooper K; Matcham J; Helme K; Akehurst R
    Int J Technol Assess Health Care; 2014 Jan; 30(1):129-130. PubMed ID: 24485057
    [No Abstract]   [Full Text] [Related]  

  • 26. [Management of refractory ITP with thrombopoietin receptor agonists].
    Tomiyama Y
    Rinsho Ketsueki; 2011 Aug; 52(8):627-32. PubMed ID: 21897068
    [No Abstract]   [Full Text] [Related]  

  • 27. Immune thrombocytopenia during childhood: new approaches to classification and management.
    Buchanan GR
    J Pediatr; 2014 Sep; 165(3):437-9. PubMed ID: 24973290
    [No Abstract]   [Full Text] [Related]  

  • 28. [Development of thrombopoietin receptor agonists].
    Miyakawa Y
    Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
    [No Abstract]   [Full Text] [Related]  

  • 29. New options after first-line therapy for chronic immune thrombocytopenic purpura.
    Burzynski J
    Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S11-21. PubMed ID: 19139486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim.
    Zimrin A; Chumsri S
    Ann Hematol; 2013 Aug; 92(8):1145-6. PubMed ID: 23328792
    [No Abstract]   [Full Text] [Related]  

  • 31. Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data.
    Altomare I; Wasser J; Pullarkat V
    Am J Hematol; 2012 Oct; 87(10):984-7. PubMed ID: 22729832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging strategies to treat chronic immune thrombocytopenic purpura.
    Newland A
    Eur J Haematol Suppl; 2008 Feb; (69):27-33. PubMed ID: 18211570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
    Francesco R
    Eur J Haematol Suppl; 2009 Mar; (71):1-2. PubMed ID: 19200300
    [No Abstract]   [Full Text] [Related]  

  • 35. [New therapeutic possibilities in chronic ITP in adults].
    Jönsson S; Olsson B; Wadenvik H
    Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1476-9. PubMed ID: 19579436
    [No Abstract]   [Full Text] [Related]  

  • 36. Orphan disease gains second treatment option.
    Morrow T
    Manag Care; 2009 Jan; 18(1):47-9. PubMed ID: 19186672
    [No Abstract]   [Full Text] [Related]  

  • 37. Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.
    Tamary H; Roganovic J; Chitlur M; Nugent DJ
    Ann Hematol; 2010 Jul; 89 Suppl 1(Suppl 1):5-10. PubMed ID: 20358200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association of rituximab and a thrombopoietin receptor agonist in high-risk refractory immune thrombocytopenic purpura.
    Veneri D; Soligo L; Pizzolo G; Ambrosetti A
    Blood Transfus; 2015 Oct; 13(4):694-5. PubMed ID: 26057496
    [No Abstract]   [Full Text] [Related]  

  • 39. Overview of thrombopoietic agents in the treatment of thrombocytopenia.
    Kobos R; Bussel JB
    Clin Lymphoma Myeloma; 2008 Feb; 8(1):33-43. PubMed ID: 18501086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of immune thrombocytopenia in elderly patients.
    Lucchini E; Fanin R; Cooper N; Zaja F
    Eur J Intern Med; 2018 Dec; 58():70-76. PubMed ID: 30274902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.